CD38 and acute lymphoblastic leukemia: It is FDA-approved for adults with relapsed multiple myeloma in combination with chemotherapy [72] and has been identified as an attractive agent for relapsed T-ALL due to robust CD38 surface expression on T-ALL lymphoblasts.